The U.S. has more thalidomide survivors than the government admits

In the 1950s and 1960s, pregnant patients were given thalidomide without their knowledge and without FDA approval, resulting in birth defects in thousands of children. Decades later, many of those survivors are still seeking official recognition from the U.S. government. Their campaign highlights ongoing gaps in regulatory accountability and the long shadow of pharmaceutical history.

The Atomic take

The gap between official thalidomide counts and the survivors seeking recognition reveals how poorly the U.S. tracked a drug that was never even FDA-approved, leaving affected people without documentation decades later. This matters for longevity because these survivors are now aging into their 60s and 70s with lifelong disabilities that federal health systems still fail to formally acknowledge or support. Watch whether official recognition unlocks medical and financial resources for an aging cohort, and whether the case reshapes how regulators document harm from off-label and unapproved drug use going forward.

Related in Longevity